menu
    • menu
    [{"orgOrder":0,"company":"InFlectis BioScience","sponsor":"Qualissima | Assistance Publique Hopitaux De Marseille | Stragen Pharma SA | Eurofins CDMO","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Sephin1","moa":"PPP1R15A\/PP1c phosphatase complex","graph1":"Undisclosed","graph2":"Phase I","graph3":"InFlectis BioScience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"InFlectis BioScience \/ Qualissima | Assistance Publique Hopitaux De Marseille | Stragen Pharma SA | Eurofins CDMO","highestDevelopmentStatusID":"6","companyTruncated":"InFlectis BioScience \/ Qualissima | Assistance Publique Hopitaux De Marseille | Stragen Pharma SA | Eurofins CDMO"},{"orgOrder":0,"company":"InFlectis BioScience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Sephin1","moa":"PPP1R15A\/PP1c phosphatase complex","graph1":"Neurology","graph2":"Phase II","graph3":"InFlectis BioScience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InFlectis BioScience \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"InFlectis BioScience \/ Undisclosed"},{"orgOrder":0,"company":"University of Chicago","sponsor":"Inflectis Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Sephin1","moa":"PPP1R15A\/PP1c phosphatase complex","graph1":"Genetic Disease","graph2":"Phase I","graph3":"University of Chicago","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"University of Chicago \/ Inflectis Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"University of Chicago \/ Inflectis Bioscience"}]

    Find Clinical Drug Pipeline Developments & Deals for Sephin1

    Menu

    Sephin1

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            InFlectis BioScience

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            InFlectis BioScience

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sephin1

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol)

                            Details : IFB-088 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 19, 2022

                            Lead Product(s) : Sephin1

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            University of Chicago

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            University of Chicago

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sephin1

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Inflectis Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            InFlectis BioScience Licenses Rights to a Potential New Class of Therapies for Demyelinating Diseases from The...

                            Details : IFB-088 is entering Phase 2 clinical trials for the treatment of ALS and CMT and has shown encouraging preclinical results for the treatment of multiple sclerosis (MS).

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 22, 2021

                            Lead Product(s) : Sephin1

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Inflectis Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            InFlectis BioScience

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            InFlectis BioScience

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sephin1

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Qualissima | Assistance Publique Hopitaux De Marseille | Stragen Pharma SA | Eurofins CDMO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Combined SAD and MAD Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of IFB-088

                            Details : IFB-088 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 01, 2018

                            Lead Product(s) : Sephin1

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Qualissima | Assistance Publique Hopitaux De Marseille | Stragen Pharma SA | Eurofins CDMO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth